1. Home
  2. ABCL

as 06-13-2024 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company have extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.

Founded: 2012 Country:
Canada
Canada
Employees: N/A City: VANCOUVER
Market Cap: 1.1B IPO Year: 2020
Target Price: $17.00 AVG Volume (30 days): 1.3M
Analyst Decision: Strong Buy Number of Analysts: 5
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -0.52 EPS Growth: N/A
52 Week Low/High: $3.31 - $8.05 Next Earning Date: 08-01-2024
Revenue: $35,788,000 Revenue Growth: -80.23%
Revenue Growth (this year): 11.3% Revenue Growth (next year): 26.84%

ABCL Daily Stock ML Predictions

Stock Insider Trading Activity of AbCellera Biologics Inc. (ABCL)

Name Ticker Relationship Date Transaction Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
Montalbano John S. ABCL Director Nov 6 '23 Buy $4.64 20,000 $92,800.00 76,000 SEC Form 4
Montalbano John S. ABCL Director Nov 6 '23 Buy $4.46 10,000 $44,600.00 86,000 SEC Form 4

Share on Social Networks: